Whitehawk Therapeutics Inc (WHWK) Stock Score, Valuation & Financial Research

Whitehawk Therapeutics Inc is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for WHWK

Whitehawk Therapeutics Inc does not currently have a complete Wall Street Score. The stored market price is USD 3.56. These figures are a research snapshot, not a buy or sell recommendation.

What Whitehawk Therapeutics Inc does

Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Whitehawk Therapeutics is a clinical-stage oncology company focused on developing antibody drug conjugates (ADC) to treat cancer. The company previously generated revenue through the commercial sale of FYARRO, a nab-sirolimus treatment, but divested this business in March 2025 and is now transitioning to a research and development-focused model.

Products and services

  • The company is developing a portfolio of next-generation antibody drug conjugates (ADC) for cancer treatment. It previously marketed FYARRO (nab-sirolimus) for the treatment of advanced malignant PEComa.

Brands and product families

  • FYARRO — A nab-sirolimus treatment for advanced malignant PEComa; business divested in March 2025. Source

Annual revenue by business

  • Product: USD 7,145,000 · 100.00% calculated revenue share (period 2025-12-31) Source

Revenue share is not a unit-sales or best-seller ranking. Categories may overlap; do not add rows from different breakdowns.

Customer types

Oncology patients.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company utilizes third-party contract manufacturing organizations for the development and production of its therapeutic candidates; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • WuXi Biologics — Contract manufacturing and development partner for the company's ADC assets. Source
  • Hangzhou DAC — Contract manufacturing and development partner for the company's ADC assets. Source

Business risks and research considerations

  • Clinical development and regulatory approval risks for oncology pipeline Source
  • Dependence on third-party contract manufacturing organizations Source

Sources: Company research source · Product · WuXi Biologics

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

WHWK financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 3.56
Market capitalization:
202.95M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -79.83M
Free cash flow:
USD -97.99M
Cash:
USD 85.23M
Total debt:
USD 0.00
EPS:
USD -1.12

What stands out

  • Reported year-over-year revenue growth is -100.0%.
  • Free cash flow is USD -97.99M, negative for the stored period.
  • The balance sheet shows USD 85.23M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 85.23M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for WHWK

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • What is driving WHWK's revenue decline, and does the latest filing suggest the weakness is temporary or structural?
  • How long can WHWK fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is WHWK likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for WHWK to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of WHWK's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research WHWK

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.